Authors
Latest:
Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung CancerOriginal research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.
Latest:
Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer OrganizationsAlthough female representation for National Comprehensive Cancer Network guidelines has increased to at least 50%, participation in guideline panels across all organizations is still less than 30%.
Latest:
Life-Saving Surgery in Lung Cancer May Be Uncovered Through Information-SeekingStage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Latest:
Communication Between Leadership and Clinicians Improves Cancer CareLeaders of a new cancer center, which is part of JFK University Medical Center, discuss how they can support frontline clinicians.
Latest:
Future Perspectives: What’s Next in NDMM?Panelists discuss how the treatment landscape for patients with transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM) is expected to evolve, with considerations for optimizing therapeutic approaches based on emerging data from novel drug combinations and treatment strategies.
Latest:
Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic ReviewDanazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
Latest:
Exploring the Future of ctDNA and Novel Treatment StrategiesPanelists offer concluding perspectives on the future role of circulating tumor DNA in colorectal cancer management.
Latest:
Modifying Radioactive Injection Techniques May Decrease Extravasation RateA study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Latest:
Lindsey Roeker, MD, Discusses Potential for BTK Inhibition Plus Umbralisib/Ublituximab in CLLLindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.
Latest:
Alicia Morgans, MD, MPH, Discusses Outcomes From the CARD Trial in mCRPC at 2021 ESMOCancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.
Latest:
Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk StratificationThis study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
Latest:
Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled TrialsThe aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.
Latest:
Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROCA phase 2 trial found that pembrolizumab plus lenvatinib elicited an overall response rate of 37.5% that consisted entirely of partial responses in high-grade serous PROC.
Latest:
CAR T, Targeted Therapies, Others as Treatment Options on the Horizon in NETsThe NETRF lends funding to help discover new and emerging treatment options in neuroendocrine tumors, according to Anna Greene, PhD.
Latest:
Emerging Strategies to Manage Relapsed and/or Refractory Multiple MyelomaJames J. Driscoll, MD, PhD, and James Ignatz-Hoover, MD, PhD, share a perspective on a study published recently in ONCOLOGY.
Latest:
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and TreatmentSurvivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Breaking Down the Phase 2 LASER trial of 177Lu-PSMA-617 in Clear Cell RCC“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Praful Ravi, MB, BChir, MRCP, on the phase 2 LASER trial in RCC.
